Recent Quotes (30 days)

You have no recent quotes
chg | %

Dechra Pharmaceuticals plc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

DPH 1,422.00 -17.00 (-1.18%)
price chart
Dechra� Pharmaceuticals PLC Trading Update
International specialist veterinary pharmaceuticals and related products business, Dechra Pharmaceuticals PLC (Dechra or the Company) (Stock Code: Full Listing (Pharmaceuticals): DPH) issues the following unaudited Trading Update covering the half year ...
TOP NEWS: Dechra Sales Boosted By Acquisitions And Weak Pound  London South East (registration) (blog)
Dechra Pharmaceuticals plc 7.8% Potential Upside Indicated by Cantor Fitzgerald
Dechra Pharmaceuticals plc with EPIC/TICKER LON:DPH had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' today by analysts at Cantor Fitzgerald.
Dechra Pharmaceuticals plc's (DPH) "Under Review" Rating ...  Sports Perspectives
Dechra Pharmaceuticals plc (DPH) Given Add Rating at Numis Securities Ltd  The Cerbat Gem
Dechra Pharmaceuticals PLC: Annual Results
Dechra is an international specialist veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide.
Is Dechra Pharmaceuticals plc a better buy than GlaxoSmithKline plc after ...  Motley Fool UK
Dechra Pharmaceuticals PLC, Agrees Acquisition of US-based Putney, Inc for ...
Dechra Pharmaceuticals PLC (LSE: symbol DPH) announces the conditional acquisition of the entire share capital of Putney, Inc, a leading developer of generic companion animal pharmaceuticals in the US, based in Portland, Maine.
Dechra to acquire Putney, maker of generic veterinary drugs, for $200 million  dvm360
Dechra Pharmaceuticals PLC: Half-Yearly Financial Report 2016
"All our business units are performing well, we are in the process of launching several new products, our international expansion plans are progressing as expected and we have made two strategic acquisitions.
Are RhythmOne plc, Dechra Pharmaceuticals plc and Pagegroup plc 'buys' after ...
Also reporting today was Dechra Pharmaceuticals (LSE: DPH). Its trading in the most recent full year was strong, with revenue rising by 21%.
Dechra� Pharmaceuticals PLC: Trading Update & Notice of 2016 Annual Results  PR Newswire (press release)
Dechra Pharmaceuticals plc (DPH) Stock Rating Reaffirmed by Numis Securities Ltd
Dechra Pharmaceuticals plc logo Dechra Pharmaceuticals plc (LON:DPH)'s stock had its “add” rating reiterated by analysts at Numis Securities Ltd in a research report issued on Tuesday.
Dechra Pharmaceuticals plc (DPH) Rating Reiterated by Panmure Gordon  The Cerbat Gem
Dechra Pharmaceuticals (LON:DPH) Broker Roundup  The De Soto Edge
The Brokerages Set Dechra Pharmaceuticals plc (DPH) Price Target at $1337.43
Dechra Pharmaceuticals plc (LON:DPH) has earned an average recommendation of “Buy” from the eight analysts that are covering the firm.
Are GlaxoSmithKline plc, Dechra Pharmaceuticals plc & CareTech Holdings plc On ...
For example, Dechra (LSE: DPH) has been able to increase its earnings at a double-digit rate in each of the last three years, with it rising at an annualised rate of 23% during the period.
Brokerages Set Dechra Pharmaceuticals plc (DPH) Price Target at $1337.43
Dechra Pharmaceuticals plc logo Shares of Dechra Pharmaceuticals plc (LON:DPH) have been given an average recommendation of “Buy” by the eight research firms that are presently covering the company.